Viit Health

How can a light help you live longer? Viit Health has made it possible.

This startup has created a pocket-sized device that uses light and Artificial Intelligence (AI) to accurately measure key biomarkers like blood glucose, blood pressure, oxygen saturation, and heart rate.

In doing so, this device monitors users’ health and offers real-time personalized insights, all while detecting early signs of health risks and helping people stay healthy for longer.

Every two seconds, someone dies from a preventable disease. Non-communicable diseases like hypertension, heart disease, diabetes, and other metabolic disorders now account for more than seventy percent of deaths globally, claiming more than forty million lives per year.

Often symptomless in early stages, conditions like high blood pressure or glucose-related dysfunction progress silently until disease becomes unavoidable. These threats, driven by sedentary lifestyles, poor nutrition, chronic stress, and inadequate access to healthcare, can lead to heart attacks, strokes, and kidney failure.

Bottom line: the crisis isn’t just a medical one — it’s a failure of early detection and accessible prevention.

Monitoring vital health markers like blood glucose, blood pressure, and oxygen saturation remains a slow, fragmented process. Individuals often need multiple devices, each requiring setup, calibration, and manual interpretation.

Blood-glucose tracking, for example, still relies on painful finger pricks or expensive continuous monitors that can cost up to $3,600 a year. At the clinic level, conducting a full assessment of basic vitals can take nearly twenty minutes and cost nearly seven dollars per patient. These inefficiencies not only drive up costs, but discourage consistent monitoring, delay diagnosis, and ultimately make prevention inaccessible for millions.

This is where Viit Health can make an impact with its device. Here’s how it works:

Viit combines Near Infrared Transmittance Spectroscopy (NIRS-TA), Photoplethysmography, Light Rotation, and AI to deliver fast, painless, non-invasive readings of key health biomarkers — without the need for multiple devices, finger pricks, or consumables.

During each reading, specific molecular bonds absorb light at characteristic wavelengths. Then, blood flow alters the amount of light absorbed.

From there, optically-active molecules rotate the plane of polarized light. And finally, AI models trained on millions of data points identify correlations.

What traditionally takes up to twenty minutes and seven dollars per patient can now be done in less than thirty seconds and cost as little as ten cents per scan. This represents a ninety-seven-percent savings in time and ninety-five-percent savings in cost.

Viit has spent more than six years developing and testing its technology. Since 2018, it’s collaborated with healthcare institutions in the U.S. and Mexico, conducting four clinical studies and validating its technology in more than 3,700 individuals.

The company’s business model is designed for both access and long0term impact. It’s launching a dual path: a reimbursable subscription model for clinics, healthcare providers, and public-health programs (starting at $250 per month per device), and an affordable wellness subscription for individuals focused on prevention and metabolic health (starting at $10 per month).

With its device, Viit is targeting a $780 billion market that includes investments in public health, prevention, and personalized medicine. Its initial target sector includes women, children, and elderly patients in North and Latin America, which is a market valued at close to three billion dollars.

Viit has received four research & development grants and was a global finalist at the 2022 Startup Worldcup, a global competition showcasing the best startups and ideas.

By the end of this year, Viit expects to finalize the commercial-ready iteration of its monitoring device, with market entry planned for 2026 following additional clinical studies and regulatory submissions already underway. Commercial clearance as a prevention tool is anticipated by mid-2026.

Revenue projections for 2026 are around $200,000, followed by $2.7 million in 2027 and $12.9 million in 2028.

Longer-term, Viit aims to have its device capable of monitoring additional biomarkers such as cholesterol levels, insulin, respiratory rate, triglycerides, and oxydative stress levels.

Team Background

Luis Gomez - Chief Executive Officer

Luis is a serial entrepreneur who has launched more than half a dozen startups and achieved two exits.

Prior to Viit Health, he was President of Bauns, a consumer-services company enabling people to rent remote-working stations. Before that, he co-founded Bildout, a Mexico-based technology company.

He won the Santander X Challenge, a startup competition, in 2020 and was a Startup World Cup finalist in 2022.

Mayra Mora - Chief Technology Officer

Mayra joined Viit Health in March 2025. Before that, she was a Professor of Engineering at Universidad Anahuac, teaching computer science and programming.

For four years, she was a consultant for a number of medical-technology startups, guiding them through product development, regulatory compliance, and intellectual-property protection. Before that, she was Chief Technology Officer with Juno Lab, a medical company focused on improving childbirth outcomes.

Earlier in her career, Mayra was a biomedical engineer with Biomdex, a medical-equipment manufacturer. Prior to that, she was a research assistant with Arts et Metiers ParisTech, an engineering school, where she focused on surgical planning for cancer treatment.

She earned a Bachelor’s degree in Engineering from Universidad Anahuac, a Master’s degree in Biomedical Engineering from Universite Paris, and a Master’s degree in Biomechanics from Arts et Metiers.

Antonio Garcia - Chief Science Officer

Antonio leads research on bio-nanotechnology and diagnostics. He has had nearly 150 publications and received funding from the National Institutes of Health and National Science Foundation.

For thirty years, he was a Professor of Bioengineering at Arizona State University, and then became Associate Dean of Academic Affairs at New Mexico State University. He continues today as a bio-nanotechnology inventor and consultant.

Antonio earned a Bachelor’s degree in Chemical Engineering from Rutgers University and a Ph.D. in Chemical Engineering from UC Berkeley.

Co-Investors